Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Downgraded by BidaskClub
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) was downgraded by equities researchers at BidaskClub from a “hold” rating to a “sell” rating in a research note issued to investors on Friday.
A number of other research firms also recently weighed in on COLL. Zacks Investment Research downgraded shares of Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. Piper Jaffray Companies set a $14.00 price target on shares of Collegium Pharmaceutical and gave the company a “buy” rating in a research report on Tuesday, July 25th. ValuEngine upgraded shares of Collegium Pharmaceutical from a “strong sell” rating to a “sell” rating in a research report on Thursday, June 22nd. Janney Montgomery Scott reiterated a “buy” rating and issued a $25.00 price target on shares of Collegium Pharmaceutical in a research report on Monday, June 12th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $25.00 price target on shares of Collegium Pharmaceutical in a research report on Friday, June 9th. Three investment analysts have rated the stock with a sell rating and five have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $21.33.
Collegium Pharmaceutical (COLL) traded up 2.44% during mid-day trading on Friday, hitting $11.32. The company had a trading volume of 398,002 shares. The company’s market cap is $333.46 million. The company’s 50 day moving average price is $12.18 and its 200-day moving average price is $12.12. Collegium Pharmaceutical has a one year low of $7.37 and a one year high of $20.55.
Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings data on Wednesday, May 10th. The specialty pharmaceutical company reported ($0.79) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.98) by $0.19. The firm had revenue of $2.17 million for the quarter, compared to the consensus estimate of $3.55 million. Equities research analysts anticipate that Collegium Pharmaceutical will post ($3.14) EPS for the current fiscal year.
In other Collegium Pharmaceutical news, insider Paul Brannelly purchased 10,000 shares of the company’s stock in a transaction dated Friday, May 12th. The stock was bought at an average cost of $9.18 per share, for a total transaction of $91,800.00. Following the completion of the transaction, the insider now owns 110,227 shares in the company, valued at $1,011,883.86. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 25.76% of the stock is currently owned by insiders.
Several large investors have recently added to or reduced their stakes in COLL. Dynamic Technology Lab Private Ltd acquired a new stake in Collegium Pharmaceutical during the first quarter worth $238,000. American International Group Inc. increased its position in shares of Collegium Pharmaceutical by 27.8% in the first quarter. American International Group Inc. now owns 9,948 shares of the specialty pharmaceutical company’s stock valued at $100,000 after buying an additional 2,163 shares in the last quarter. Pier Capital LLC increased its position in shares of Collegium Pharmaceutical by 11.1% in the first quarter. Pier Capital LLC now owns 366,064 shares of the specialty pharmaceutical company’s stock valued at $3,683,000 after buying an additional 36,435 shares in the last quarter. Trexquant Investment LP purchased a new position in shares of Collegium Pharmaceutical during the first quarter valued at approximately $259,000. Finally, Bank of New York Mellon Corp increased its position in shares of Collegium Pharmaceutical by 6.1% in the first quarter. Bank of New York Mellon Corp now owns 65,305 shares of the specialty pharmaceutical company’s stock valued at $656,000 after buying an additional 3,775 shares in the last quarter. Institutional investors own 82.36% of the company’s stock.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.
Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.